Cargando…

MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

BACKGROUND: Erenumab was approved in Europe for migraine prevention in patients with ≥ 4 monthly migraine days (MMDs). In Spain, Novartis started a personalized managed access program, which allowed free access to erenumab before official reimbursement. The Spanish Neurological Society started a pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belvís, Robert, Irimia, Pablo, Pozo-Rosich, Patricia, González-Oria, Carmen, Cano, Antonio, Viguera, Javier, Sánchez, Belén, Molina, Francisco, Beltrán, Isabel, Oterino, Agustín, Cuadrado, Elisa, Gómez-Camello, Angel, Alberte-Woodward, Miguel, Jurado, Carmen, Oms, Teresa, Ezpeleta, David, de Terán, Javier Díaz, Morollón, Noemí, Latorre, Germán, Torres-Ferrús, Marta, Alpuente, Alicia, Lamas, Raquel, Toledano, Carlos, Leira, Rogelio, Santos, Sonia, del Río, Margarita Sánchez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8285868/ https://www.ncbi.nlm.nih.gov/pubmed/34273947 http://dx.doi.org/10.1186/s10194-021-01267-x

Ejemplares similares

A study of differential microRNA expression profile in migraine: the microMIG exploratory study
por: Gallardo, V. J., et al.
Publicado: (2023)

Influence of headache pain intensity and frequency on migraine-related disability in chronic migraine patients treated with OnabotulinumtoxinA
por: Torres-Ferrus, Marta, et al.
Publicado: (2020)

Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months
por: Caronna, Edoardo, et al.
Publicado: (2021)

In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study
por: Alpuente, Alicia, et al.
Publicado: (2021)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications
por: Caronna, E., et al.
Publicado: (2021)

Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology’s Headache Study Group()
por: Morollón, N., et al.
Publicado: (2020)

Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología
por: Morollón, N., et al.
Publicado: (2020)

Combinatorial control of gene expression by the three yeast repressors Mig1, Mig2 and Mig3
por: Westholm, Jakub Orzechowski, et al.
Publicado: (2008)

Cutaneous Allodynia in Migraine: A Narrative Review
por: Mínguez-Olaondo, Ane, et al.
Publicado: (2022)

The role of erenumab in the treatment of migraine
por: Andreou, Anna P., et al.
Publicado: (2020)

Post-COVID-19 fatigue: the contribution of cognitive and neuropsychiatric symptoms
por: Calabria, Marco, et al.
Publicado: (2022)

Gender Differences in 3-Month Outcomes of Erenumab Treatment—Study on Efficacy and Safety of Treatment With Erenumab in Men
por: Ornello, Raffaele, et al.
Publicado: (2021)

Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)

Clinic and genetic predictors in response to erenumab
por: Zecca, Chiara, et al.
Publicado: (2022)

Lichenoid drug eruption induced by erenumab
por: Musicante, Meryl, et al.
Publicado: (2022)

Assessment and characteristics of Erenumab therapy on migraine management
por: Saeed, Haitham, et al.
Publicado: (2022)

Evaluating glaucoma surgeries in the MIGS context
por: Dhingra, Deepika, et al.
Publicado: (2020)

Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients
por: Muñoz-Vendrell, Albert, et al.
Publicado: (2023)

Roles of Candida albicans Mig1 and Mig2 in glucose repression, pathogenicity traits, and SNF1 essentiality
por: Lagree, Katherine, et al.
Publicado: (2020)

A longitudinal clinical and MRI evaluation of the treatment with erenumab
por: Coccia, Alberto, et al.
Publicado: (2020)

Predictors of response to erenumab after 12 months of treatment
por: Baraldi, Carlo, et al.
Publicado: (2021)

Timing and durability of response to erenumab in patients with chronic migraine
por: Tepper, Stewart J., et al.
Publicado: (2021)

Myocardial infarction associated with erenumab: A case report
por: Perino, Justine, et al.
Publicado: (2022)

Efficacy and Tolerability of Erenumab for Prevention of Episodic Migraine in India
por: Chowdhury, Debashish, et al.
Publicado: (2022)

Erenumab in the Treatment of Comorbid Trigeminal Neuralgia in Patients With Migraine
por: Katsuki, Masahito, et al.
Publicado: (2023)

Cortical metabolic and structural differences in patients with chronic migraine. An exploratory (18)FDG-PET and MRI study
por: Torres-Ferrus, Marta, et al.
Publicado: (2021)

Neuropsychological deficits in patients with cognitive complaints after COVID‐19
por: García‐Sánchez, Carmen, et al.
Publicado: (2022)

Human Mig chemokine: biochemical and functional characterization
Publicado: (1995)

EHMTI-0103. Errors in recognition and management are still frequent in cluster headache
por: del Río, M Sánchez, et al.
Publicado: (2014)

Exploring sensory sensitivity, cortical excitability, and habituation in episodic migraine, as a function of age and disease severity, using the pattern-reversal task
por: Marti-Marca, Angela, et al.
Publicado: (2023)

Pancreatic loss of Mig6 alters murine endocrine cell fate and protects functional beta cell mass in an STZ-induced model of diabetes
por: Bauer, Brandon M., et al.
Publicado: (2023)

Efficacy and safety of erenumab in women with a history of menstrual migraine
por: Pavlovic, Jelena M., et al.
Publicado: (2020)

Early onset of efficacy with erenumab in patients with episodic and chronic migraine
por: Schwedt, Todd, et al.
Publicado: (2018)

Raynaud's phenomenon secondary to erenumab in a patient with chronic migraine
por: Manickam, Agaath Hedina, et al.
Publicado: (2021)

Migraine Prevention with Erenumab: Focus on Patient Selection, Perspectives and Outcomes
por: De Matteis, Eleonora, et al.
Publicado: (2022)

Serum CGRP in migraine patients using erenumab as preventive treatment
por: de Vries Lentsch, Simone, et al.
Publicado: (2022)

Status Report from the Machine Interface Group (MIG)
por: MIG Group
Publicado: (1987)

An Update on Implants for Minimally Invasive Glaucoma Surgery (MIGS)
por: Ansari, Ejaz
Publicado: (2017)

Effects of Schlemm’s Canal Expansion: Biomechanics and MIGS Implications
por: Xin, Chen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g1muhhphpfbqiq49m0trvn0rab